BioWorld

Nov. 4, 2008

Telaprevir Takes Center Stage as New HCV Approaches Advance

As analysts predicted, the data coming out of embargo during the annual meeting of the American Association for the Study of Liver Disease (AASLD) don't appear to be triggering any major swings in biotech stock prices. (BioWorld Today) Read More

Top FDA Career Officials Opposed Preemption Rules

Scientists Target Immune System Microenvironment to Strike Tumor

Genentech Seeks Avastin Use for Aggressive Brain Cancer

Avigen Cutting Staff 70% After Tolperisone Failure

Cephalon's Treanda OK'd for Second Cancer Indication

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...